Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47)

  • STATUS
    Recruiting
  • End date
    Nov 30, 2028
  • participants needed
    33
  • sponsor
    University of Virginia
Updated on 31 January 2022
ct scan
estrogen
serum pregnancy test
measurable disease
breast cancer
international normalized ratio
progesterone
metastasis
neutrophil count
HER2
aptt
thromboplastin
progesterone receptor

Summary

This proposal uses HER2Bi armed activated T-cells (HER2 BATs) to target breast cancer in combination with pembrolizumab (PBZ) in women with metastatic breast cancer (MBC). Phase I will determine a safe dose of the combination of PBZ and HER2 BATs in 3 to 18 patients. In the phase II portion, an additional 12 patients will be treated at the selected dose to further evaluate the safety and preliminary efficacy.

Study treatment includes a combination of 8 infusions of BATs using a previously established schedule and one to three infusions of PBZ (200 mg per dose). PBZ will be added to 8 infusions of BATs in 3 schedules: #1) after the 8th BATs infusion; #2) after the 4th and 8th BATs infusions; and then, #3) before the 1st and after the 4th and 8th BATs infusions.

Description

Once subjects are determined eligible, white blood cells (lymphocytes) are collected via leukapheresis procedure. Depending on arm/schedule, about 4-5 weeks later, study treatment will begin. For HER2 BATs, the white blood cells, specifically T cells, are then mixed with two proteins - OKT3 and IL-2 -- which activates the cells to multiply. After approximately 14 days in culture, the activated T cells are coated with OKT3 and trastuzumab/Herceptin (HER2Bi), and washed to remove excess Herceptin in order to produce bispecific antibody armed T cells (BATs). Cells are then frozen and stored until scheduled to be infused.

Follow-up appointment schedule will include clinic visits 2 weeks, 1 month, 3 months, and 6 months after the last dose of Pembrolizumab.

Details
Condition Metastatic Breast Cancer
Treatment HER2 BATs with Pembrolizumab
Clinical Study IdentifierNCT03272334
SponsorUniversity of Virginia
Last Modified on31 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically confirmed breast cancer (infiltrating ductal or lobular breast carcinoma) with evidence of measurable metastatic disease. Metastatic disease must be biopsy proven
Since histologic type, lymphatic permeation, blood vessel invasion, and degree of anaplasia may be prognostic variables, appropriate slides of the primary lesion will be requested for future review. HER2, estrogen, and progesterone receptor positivity will be recorded
Measurable lesion. Patients are required to have at least one measurable non-bone lesion 10 mm that has not been irradiated
Measurable metastatic disease documented by radiograph, CT scan, PET/CT, MRI, or physical exam is required. Each subject will be required to have at least one measurable lesion that has not been irradiated with a minimum size in at least one diameter of 10 mm for liver lesions, lung, skin, and 15 mm lymph node metastases. Biopsy of recurrent site(s) is not required
Patients must have HER2 status determined by FISH or IHC. HER2 status of positive or negative are both eligible for the study
In order to be eligible for participation in this trial, the patient must
also
\. Be female 18 years of age
\. Be willing and able to provide written informed consent for the trial
\. Have a performance status (PS) ECOG 0-1
\. Have a life expectancy 3 months
\. Be eligible for apheresis, as determined by the Stem Cell Transplant team
\. Demonstrate adequate organ function as defined below, all screening labs
should be performed within 10 days prior to apheresis
Absolute lymphocyte count 500/mm3 Absolute neutrophil count (ANC) 1,500 /mcL
Platelets 100,000 / mcL Hemoglobin 9 g/dL (or 5.6 mmol/L without transfusion
or EPO dependency (within 7 days of assessment) BUN 1.5 X upper limit of
normal (ULN) Serum creatinine OR 1.5 X upper limit of normal (ULN) OR Measured
or calculated creatinine clearance (GFR can also be used in place of
creatinine or CrCl) 60 mL/min for subject with creatinine levels > 1.5 X
institutional ULN Serum total bilirubin 1.5 X ULN OR AST (SGOT) and ALT (SGPT)
5 X ULN OR 5 X ULN for subjects with liver metastases Albumin >2.5 mg/dL
International Normalized Ratio (INR) or Prothrombin Time (PT) 1.5 X ULN unless
subject is receiving anticoagulant therapy Activated Partial Thromboplastin
Time (aPTT) as long as PT or PTT is within therapeutic range of intended use
of anticoagulants
\. Female patients of childbearing potential should have a negative urine or
serum pregnancy test at screening. If the urine test is positive or cannot be
confirmed as negative, a serum pregnancy test will be required
\. Female patients of childbearing potential must be willing to use an
adequate method of contraception as outlined in Section 4.5.2, for the course
of the study through 120 days after the last dose of study medication
\. Patients must have had two or more lines of prior therapy (chemo or
hormonal) in the metastatic setting

Exclusion Criteria

The patient must be excluded from participating in the trial if the subject
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to leukapheresis
Has a known history of active TB (Bacillus Tuberculosis)
Hypersensitivity to PBZ or any of its excipients
Lack of recovery (i.e., Grade 1 or baseline prior to last line of cancer therapy) from non-laboratory adverse events except Grade 2 neuropathy
Has history of another malignancy within the past 5 years. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to leukapheresis. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
Has known history of, or any evidence of active, non-infectious pneumonitis
Has an active infection requiring systemic therapy
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
Is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or known history of Hepatitis B (e.g., HBsAg reactive) or Hepatitis C antibody is detected. Note: Patients may be eligible if HCV antibody is detected as long as HCV viral load is undetectable following an FDA approved treatment regimen
Has received a live vaccine within 30 days of apheresis. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed
Has a history of significant cardiac disease, including
History of a recent myocardial infarction (within one year), a past myocardial infarction (more than one year ago) along with current coronary symptoms requiring medications and/or evidence of depressed left ventricular function (LVEF < 45% by MUGA or ECHO)
Current history of angina/coronary symptoms requiring medications and/or evidence of depressed left ventricular function (LVEF < 45% by MUGA or ECHO)
Clinical evidence of congestive heart failure requiring medical management (irrespective of ECHO results)
Pt may be excluded if, in the opinion of the PI and investigator team, the pt is not capable of being compliant
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note